methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate | 1158233-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate
• CAS: 1158233-60-3
• 化学式: C₁₂H₁₁ClN₂O₃
• mdl: MFCD11852612
• 分子量: 266.684
• InChiKey: UAUZQCNSSYMAGD-UHFFFAOYSA-N

物化性质

• 沸点：
  426.9±40.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  64.35
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate 在 sodium methylate 、 溶剂黄146 作用下， 以 甲醇 、 异丙醇 、 乙腈 为溶剂， 反应 1.0h， 生成 10-benzyl-2-(2-chlorophenyl)-2,3,8,9,10,11-hexahydro-1H-pyrazolo[4',3':3,4]pyrido[1,2-a][1,4]diazepine-1,5(7H)-dione
  参考文献：
  名称：

  Pyrazoline dione derivatives as nadph oxidase inhibitors

  摘要：

  本发明涉及式(I)的吡唑烷二酮衍生物，其药物组成部分以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酸化酶（NADPH氧化酶）相关的疾病或症状。

  公开号：

  EP2305679A1
• 作为产物：
  描述：

  (2-氯苯基)-肼 在 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate
  参考文献：
  名称：

  [EN] PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  [FR] DÉRIVÉS DE PYRAZOLINE DIONE UTILISÉS EN TANT QU'INHIBITEURS DE NADPH OXYDASE

  摘要：

  本发明涉及式（I）的吡唑烯二酮衍生物，其制药组合物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。

  公开号：

  WO2011036651A1

文献信息

• Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
  申请人：GENKYO TEX SA

  公开号：EP2166008A1

  公开（公告）日：2010-03-24

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑吡啶衍生物，其药物组合物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。
• PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20110269757A1

  公开（公告）日：2011-11-03

  The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的吡唑吡啶衍生物，其制药组合物以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）有关的疾病或症状的用途。
• PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20120172352A1

  公开（公告）日：2012-07-05

  The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑烷二酮衍生物、其制药组合物以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）相关的疾病或症状的用途。
• Pyrazoline dione derivatives as NADPH oxidase inhibitors
  申请人：Page Patrick

  公开号：US09394306B2

  公开（公告）日：2016-07-19

  The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑酮二酮衍生物、其制药组合物以及它们在治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶(NADPH氧化酶)相关的疾病或病状方面的用途。
• First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
  作者：Benoı̂t Laleu、Francesca Gaggini、Mike Orchard、Laetitia Fioraso-Cartier、Laurène Cagnon、Sophie Houngninou-Molango、Angelo Gradia、Guillaume Duboux、Cédric Merlot、Freddy Heitz、Cédric Szyndralewiez、Patrick Page

  DOI：10.1021/jm100773e

  日期：2010.11.11

  We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease. Initially, several moderately potent pyrazolopyridine dione derivatives were found during a high-throughput screening campaign. SA R investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) production, showing high potency on Nox4 and Nox1. The compounds have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms. The specificity of these compounds was confirmed in an extensive in vitro pharmacological profile, as well as in a counterscreening assay for potential ROS scavenging. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo, allowing further clinical trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.